Orion Oyj — Share Issue/Capital Change 2020

Jul 14, 2020

Disclosure 385583

Orion - Other information disclosed according to the rules of the Exchange

191,501 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE 14 JULY 2020 at 9.00 EEST

191,501 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 191,501 A shares have been converted into 191,501 B shares. The conversion has been entered into the Trade Register on 14 July 2020.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 35,251,974 A shares and 105,882,304 B shares. The number of votes of the company's shares is after the conversion 810,921,784.

Orion Corporation

Jari Karlson CFO		Olli Huotari SVP, Corporate Functions

Contact person:

Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.